Brind.

A partnership was established to commercialize VAZKEPA in Europe via an exclusive license. Aaron Berg serves as President & CEO of Amarin.

11 reports, 4 independent Updated Jul 29
Gone quiet Reached 3 outlets in its first 24 hours
Reports
11
Developments
3
Repetition
73%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

A partnership was established to commercialize VAZKEPA in Europe via an exclusive license. Aaron Berg serves as President & CEO of Amarin.

Who's involved

What this event is mainly about
Amarin (United Kingdom)Aaron Berg

How it developed

Newest first. Tap a step to see who reported it.
  1. Exclusive license focuses on commercialization across Europe for VAZKEPA.1 source
  2. Amarin confirmed its European presence, listing offices in Ireland and Zug, and confirming Aaron Berg as CEO.1 source
  3. Amarin Corporation licensed VAZKEPA to Recordati for European commercialization.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireAmarin Reports Second Quarter 2025 Financial Results -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70
  • GuruFocus.comWhat To Expect From Amarin Corp PLC (AMRN) Q2 2025 Earnings Amarin Corp PLC (NASDAQ:AMRN) is set to release its Q2 2025 earnings on July 30, 2025. The consensus estimate for Q2 2025 revenue is $53.79
  • ZacksAmarin Gears Up to Report Q2 Earnings: Here's What to Expect We expect investors to focus on the sales performance of Amarin Corporation’s AMRN sole marketed drug, Vascepa/Vazkepa, when it reports se
  • GlobeNewswireAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) t
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet